FR22C1034I1 - Rapports de médicament fixes pour le traitement des cancers hématopoïétiques et des troubles prolifératifs - Google Patents

Rapports de médicament fixes pour le traitement des cancers hématopoïétiques et des troubles prolifératifs

Info

Publication number
FR22C1034I1
FR22C1034I1 FR22C1034C FR22C1034C FR22C1034I1 FR 22C1034 I1 FR22C1034 I1 FR 22C1034I1 FR 22C1034 C FR22C1034 C FR 22C1034C FR 22C1034 C FR22C1034 C FR 22C1034C FR 22C1034 I1 FR22C1034 I1 FR 22C1034I1
Authority
FR
France
Prior art keywords
treatment
proliferative disorders
hematopoietic cancers
fixed drug
drug ratios
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR22C1034C
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rotalec Ip Holdings LLC
Original Assignee
Rotalec Ip Holdings LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39690832&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR22C1034(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rotalec Ip Holdings LLC filed Critical Rotalec Ip Holdings LLC
Publication of FR22C1034I1 publication Critical patent/FR22C1034I1/fr
Application granted granted Critical
Publication of FR22C1034I2 publication Critical patent/FR22C1034I2/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]
FR22C1034C 2007-02-16 2022-07-05 Rapports de médicament fixes pour le traitement des cancers hématopoïétiques et des troubles prolifératifs Active FR22C1034I2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US90177207P 2007-02-16 2007-02-16
US96519607P 2007-08-17 2007-08-17
EP08730048.9A EP2120568B1 (fr) 2007-02-16 2008-02-15 Rapports pharmacologiques fixes dans le traitement des cancers hématopoïétiques et des affections prolifératives
PCT/US2008/054168 WO2008101214A2 (fr) 2007-02-16 2008-02-15 Rapports pharmacologiques fixes dans le traitement des cancers hématopoïétiques et des affections prolifératives

Publications (2)

Publication Number Publication Date
FR22C1034I1 true FR22C1034I1 (fr) 2022-09-09
FR22C1034I2 FR22C1034I2 (fr) 2023-06-30

Family

ID=39690832

Family Applications (1)

Application Number Title Priority Date Filing Date
FR22C1034C Active FR22C1034I2 (fr) 2007-02-16 2022-07-05 Rapports de médicament fixes pour le traitement des cancers hématopoïétiques et des troubles prolifératifs

Country Status (20)

Country Link
US (2) US8092828B2 (fr)
EP (3) EP4046640A1 (fr)
JP (1) JP5314600B2 (fr)
KR (2) KR20100014441A (fr)
CN (1) CN105998046A (fr)
AU (1) AU2008216083B2 (fr)
CA (1) CA2678332C (fr)
CY (1) CY1119631T1 (fr)
DK (2) DK2120568T3 (fr)
ES (2) ES2650167T3 (fr)
FR (1) FR22C1034I2 (fr)
HK (1) HK1253378A1 (fr)
HR (1) HRP20220428T3 (fr)
HU (2) HUE058334T2 (fr)
NL (1) NL301185I2 (fr)
NO (1) NO2120568T3 (fr)
PL (2) PL2120568T3 (fr)
PT (2) PT3300601T (fr)
SI (1) SI3300601T1 (fr)
WO (1) WO2008101214A2 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100075937A1 (en) * 2008-09-24 2010-03-25 Hollis-Eden Pharmaceuticals, Inc. Patient populations and treatment methods
JP6133308B2 (ja) * 2011-10-21 2017-05-24 セレーター ファーマシューティカルズ インコーポレイテッド 凍結乾燥リポソーム
US20140154304A1 (en) * 2012-11-30 2014-06-05 Boehringer Ingelheim International Gmbh Combination therapy with volasertib
WO2015127172A1 (fr) * 2014-02-20 2015-08-27 Agios Pharmaceuticals, Inc. Composés thérapeutiquement actifs et leurs procédés d'utilisation
WO2015127173A1 (fr) * 2014-02-20 2015-08-27 Agios Pharmaceuticals, Inc Composés thérapeutiquement actifs et leurs procédés d'utilisation
CA3005076C (fr) * 2015-11-11 2024-01-02 Celator Pharmaceuticals, Inc. Dosages et methodes pour la selection d'un schema therapeutique pour un sujet atteint de leucemie
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
WO2019023873A1 (fr) * 2017-07-31 2019-02-07 江苏竞诺择生物医药科技有限公司 Composition de microparticules nano-lipidiques et composition pharmaceutique pour le traitement de maladies prolifératives du système hématopoïétique
CA3114002A1 (fr) * 2018-09-25 2020-04-02 Celator Pharmaceuticals, Inc. Traitement de faible intensite de troubles hematologiques
CA3127871A1 (fr) 2019-03-01 2020-09-10 Flamel Ireland Limited Compositions de gamma-hydroxybutyrate presentant une pharmacocinetique amelioree a l'etat alimente
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7850990B2 (en) * 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
CA2383259A1 (fr) * 2002-04-23 2003-10-23 Celator Technologies Inc. Composes synergiques
US20040152632A1 (en) * 2002-11-06 2004-08-05 Wyeth Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome
EP1569903A4 (fr) * 2002-11-06 2009-07-29 Celgene Corp Methodes d'utilisation d'agents inhibiteurs selectifs de la cytokine et compositions comprenant ces agents pour le traitement et la gestion de maladies myeloproliferatives
JP2006508119A (ja) * 2002-11-06 2006-03-09 ワイス 急性白血病および骨髄異形成症候群の治療のための組み合わせ療法
EP2407169A1 (fr) 2004-04-22 2012-01-18 Celator Pharmaceuticals, Inc. Formulations de combinaison d'agents d'anthracycline et analogues de la cytidine
SE0402025D0 (sv) * 2004-08-13 2004-08-13 Active Biotech Ab Treatment of hyperproliferative disease with superantigens in combination with another anticancer agent
US20090148506A1 (en) 2005-12-22 2009-06-11 Awa Dicko Liposomal formulations comprising secondary and tertiary amines and methods for preparing thereof

Also Published As

Publication number Publication date
DK2120568T3 (en) 2017-12-11
WO2008101214A3 (fr) 2008-11-20
KR20150038752A (ko) 2015-04-08
HRP20220428T3 (hr) 2022-05-27
KR20100014441A (ko) 2010-02-10
EP2120568A2 (fr) 2009-11-25
AU2008216083B2 (en) 2014-02-06
US8092828B2 (en) 2012-01-10
AU2008216083A2 (en) 2009-09-24
CA2678332C (fr) 2015-06-02
CN105998046A (zh) 2016-10-12
JP2010519224A (ja) 2010-06-03
EP3300601A1 (fr) 2018-04-04
FR22C1034I2 (fr) 2023-06-30
EP2120568B1 (fr) 2017-11-15
EP4046640A1 (fr) 2022-08-24
SI3300601T1 (sl) 2022-05-31
PT2120568T (pt) 2017-12-04
CY1119631T1 (el) 2018-04-04
HUE058334T2 (hu) 2022-07-28
US20080199515A1 (en) 2008-08-21
EP2120568A4 (fr) 2010-04-21
JP5314600B2 (ja) 2013-10-16
PT3300601T (pt) 2022-04-21
EP3300601B1 (fr) 2022-01-12
HK1253378A1 (zh) 2019-06-14
WO2008101214A2 (fr) 2008-08-21
ES2650167T3 (es) 2018-01-17
AU2008216083A1 (en) 2008-08-21
NL301185I2 (nl) 2022-07-21
DK3300601T3 (da) 2022-03-21
NO2120568T3 (fr) 2018-04-14
PL3300601T3 (pl) 2022-05-02
US20100303895A1 (en) 2010-12-02
PL2120568T3 (pl) 2018-03-30
HUS2200032I1 (hu) 2022-07-28
ES2909903T3 (es) 2022-05-10
CA2678332A1 (fr) 2008-08-21

Similar Documents

Publication Publication Date Title
FR22C1034I2 (fr) Rapports de médicament fixes pour le traitement des cancers hématopoïétiques et des troubles prolifératifs
FR2925339B1 (fr) Medicament pour le traitement du cancer du pancreas
FR2948016B1 (fr) Orthese pour le traitement de la rhizarthrose
HK1163119A1 (en) Anti cxcr4 antibodies and their use for the treatment of cancer cxcr4
FR2929946B1 (fr) Nouveaux anticorps anti-cd151 et leur utilisation pour le traitement du cancer
FR2907011B1 (fr) Utilisation de la citrulline pour le traitement des etats de denutrition
IL193936A0 (en) Compositions and methods for the treatment of immunoinflammatory disorders
EP2205236A4 (fr) Nouveaux agents pour le traitement de troubles et dysfonctionnements
FR2915102B1 (fr) Utilisation d'un anticorps anti-cxcr4 pour le traitement du cancer
FR2948687B1 (fr) Utilisation de microarn pour le traitement de pathologies respiratoires chroniques
ZA201200944B (en) Pharmaceutical compositions for the treatment of cancer and other diseases or disorders
MA44700A (fr) Combinaison d'un anticorps anti-il-10 et d'un oligonucléotide de type cpg-c pour le traitement du cancer
FR2917947B1 (fr) Composition phytosanitaire pour le traitement preventif et curatif du mildiou
FR2902320B1 (fr) Utilisation de butylated hydroxyanisole pour le traitement de la canitie
FR2910324B1 (fr) Nouveau medicament pour le traitement d'un cancer gastrique
FR2910813B1 (fr) Nouvelle utilisation therapeutique pour le traitement des leucemies
IL193943A0 (en) The use of beta- aminoalcohols for the treatment of inflammatory disorders and pain
FR2924593B1 (fr) Plaque osseuse pour le traitement de l'extremite inferieure du cubitus
PL2344166T3 (pl) Kompozycja farmaceutyczna do leczenia zaburzeń w postaci podrażnień żołądkowo-jelitowych
FR2916345B1 (fr) Dispositif pour le traitement du larmoiement de l'oeil
FR2937550B1 (fr) Utilisation de la citrulline pour le traitement et la prevention du syndrome d'ischemie-reperfusion
FR2953412B1 (fr) Medicament pour le traitement des ulceres gastro-intestinaux
IL193944A0 (en) The use beta-aminoalcohols for the treatment of inflammatory disorders and pain
FR2921061B1 (fr) Derives d'indolone pour le traitement de la malaria
FR2902321B1 (fr) Utilisation de curcumin pour le traitement de la canitie